This patient's presentation, characterized by difficulty initiating a swallow (transfer dysphagia), coughing, choking, and nasal regurgitation, is classic for oropharyngeal dysphagia. The underlying cause is most likely neuromuscular dysfunction related to his recent stroke. The hoarse voice and facial weakness further support a neurologic etiology affecting the muscles of the pharynx and upper esophagus. The most appropriate next step would be a video-fluoroscopic swallowing study.

• A) Achalasia: This is a motility disorder of the esophagus causing dysphagia to both solids and liquids, but it typically presents with the sensation of food getting stuck in the chest (esophageal dysphagia), not difficulty initiating the swallow.
• B) Esophageal stricture: This is a form of mechanical obstruction that typically causes dysphagia primarily to solids, which progresses to liquids. The sensation is of food getting stuck substernally, not difficulty with the initial swallow.
• D) Diffuse esophageal spasm: This motility disorder presents with intermittent, non-progressive dysphagia to solids and liquids, often accompanied by chest pain. It does not cause difficulty initiating a swallow.

This patient presents with several alarm features for esophageal malignancy: progressive dysphagia (solids more than liquids), significant unintentional weight loss, and age >50. Additionally, his smoking and alcohol history are significant risk factors for squamous cell carcinoma of the esophagus. The presence of these alarm features warrants prompt investigation to rule out malignancy. Upper endoscopy (EGD) with biopsy is the diagnostic test of choice in this setting as it allows for direct visualization and tissue sampling.

• A) Initiate a trial of a proton pump inhibitor: While GERD can cause strictures, the alarm features in this patient make a simple PPI trial inappropriate and potentially dangerous due to the delay in diagnosing a possible cancer.
• C) Order a barium esophagram: A barium swallow can identify a stricture or mass, but it cannot differentiate between benign and malignant causes and does not allow for biopsy. Endoscopy would still be required for a definitive diagnosis.
• D) Perform esophageal manometry: Manometry is used to evaluate esophageal motility disorders like achalasia or diffuse esophageal spasm. This patient's progressive dysphagia to solids suggests a mechanical obstruction, not a motility disorder.

This patient presents with the classic triad of Plummer-Vinson syndrome: dysphagia, iron-deficiency anemia, and an esophageal web. The dysphagia is typically intermittent and localized to the upper esophagus. Koilonychia (spoon-shaped nails) is a physical finding associated with chronic iron deficiency. The barium swallow finding of a thin membrane confirms the presence of an esophageal web.

• B) Zenker diverticulum: This is an outpouching of the pharyngeal mucosa that causes oropharyngeal dysphagia, halitosis, and regurgitation of undigested food. It does not cause iron-deficiency anemia.
• C) Systemic sclerosis: This can cause esophageal dysmotility and severe GERD, but it typically affects the lower two-thirds of the esophagus and does not form upper esophageal webs.
• D) Eosinophilic esophagitis: This condition is associated with dysphagia and food impaction, often in patients with atopic histories. It is characterized by eosinophilic infiltration of the esophageal mucosa, not webs, and is not typically associated with iron-deficiency anemia.

This patient presents with classic symptoms of uncomplicated gastroesophageal reflux disease (GERD): postprandial and nocturnal heartburn, and regurgitation. He is under 50 years old and has no alarm features (e.g., dysphagia, weight loss, anemia, hematemesis). Therefore, the most appropriate initial management is an empiric trial of a proton pump inhibitor (PPI) along with counseling on lifestyle modifications, such as weight loss, dietary changes, and elevating the head of the bed.

• A) Upper endoscopy: Endoscopy is not indicated as a first step for typical GERD symptoms in the absence of alarm features.
• B) 24-hour esophageal pH monitoring: This is the gold standard for diagnosing GERD but is reserved for patients with atypical symptoms or those who fail to respond to an empiric trial of PPIs.
• D) Barium esophagram: This test has low sensitivity for GERD and is primarily used to evaluate for structural abnormalities like strictures or hiatal hernias when dysphagia is present.

This patient has symptoms of GERD that are refractory to an adequate trial of once-daily proton pump inhibitor (PPI) therapy. Failure to respond to standard-dose PPI therapy is an indication for further investigation to confirm the diagnosis, evaluate for complications of GERD (e.g., esophagitis, stricture), and rule out alternative diagnoses (e.g., eosinophilic esophagitis, achalasia). Therefore, upper endoscopy is the most appropriate next step.

• A) Increase omeprazole to 40 mg twice daily: While optimizing PPI therapy is a management option, it is generally done after an underlying cause for refractory symptoms has been investigated. An endoscopy is needed to rule out complications or an alternative diagnosis before simply increasing the dose.
• B) Add an H2 receptor antagonist at bedtime: This can be a strategy for nocturnal acid breakthrough but is less effective than optimizing PPI therapy and does not address the need for a diagnostic evaluation in refractory GERD.
• D) Refer for anti-reflux surgery: Surgery is considered for patients with confirmed GERD who are intolerant to or do not wish to take long-term PPIs, or who have complications like a large hiatal hernia. It is not appropriate before a definitive diagnosis is confirmed and other causes are excluded.

This patient has multiple risk factors for Barrett's esophagus, a metaplastic complication of chronic GERD that predisposes to esophageal adenocarcinoma. Major risk factors include a GERD duration of >5 years, age >50, male sex, obesity, and a history of smoking. Guidelines recommend a one-time screening upper endoscopy for patients with multiple risk factors, even if their symptoms are currently controlled. This is done to detect Barrett's esophagus and any associated dysplasia.

• A) Continue current management as symptoms are controlled: While his symptoms are controlled, this approach ignores the risk of underlying malignancy, for which he has multiple risk factors.
• C) Start daily therapy with a proton pump inhibitor: While PPIs are effective for symptom control, starting them now would not address the need to screen for Barrett's esophagus, which may have already developed.
• D) Order a 24-hour esophageal pH monitoring study: This test is used to confirm a diagnosis of GERD in patients with atypical symptoms or who are refractory to treatment. It is not a screening tool for Barrett's esophagus.

The patient has an H. pylori-negative gastric ulcer, and her daily use of naproxen, a non-steroidal anti-inflammatory drug (NSAID), is the most likely cause. NSAIDs inhibit prostaglandin synthesis, which compromises the protective gastric mucosal barrier. The most critical step in managing an NSAID-induced ulcer is to discontinue the offending agent, if clinically feasible. Healing is significantly delayed if the NSAID is continued, even with aggressive acid suppression therapy.

• B) Start sucralfate therapy: Sucralfate can provide a protective coating over the ulcer but is considered an adjunctive therapy. The primary intervention is removing the cause (NSAID) and suppressing acid (PPI).
• C) Repeat endoscopy in 2 weeks: A repeat endoscopy is necessary to ensure healing of a gastric ulcer (to rule out malignancy), but it is typically performed in 8-12 weeks, not 2 weeks. The immediate priority is stopping the NSAID.
• D) Test for serum gastrin level: This is done to screen for Zollinger-Ellison syndrome, which is a rare cause of PUD. It would be considered if the ulcer is refractory to treatment or if there are multiple ulcers, but NSAID-induced ulcer is far more likely in this patient.

The urea breath test and the stool antigen test are the preferred non-invasive methods for confirming H. pylori eradication. These tests detect active infection. They should be performed at least 4 weeks after completion of antibiotic therapy and after proton pump inhibitors have been held for 1-2 weeks. Since the patient is asymptomatic and off medications, the urea breath test is an excellent choice.

• A) H. pylori serology (IgG): Serology tests for IgG antibodies against H. pylori. These antibodies can remain elevated for months to years even after successful eradication and therefore cannot be used to confirm cure.
• C) Repeat upper endoscopy with biopsy: This is an invasive method and is not necessary for confirming eradication in an asymptomatic patient with an uncomplicated ulcer. It is reserved for patients with complicated ulcers (e.g., bleeding, gastric ulcer) to ensure healing and rule out malignancy.
• D) Fecal calprotectin: This is a marker for intestinal inflammation, primarily used in the diagnosis and monitoring of inflammatory bowel disease, not for H. pylori testing.

A non-healing (refractory) gastric ulcer despite adequate high-dose PPI therapy and confirmed absence of H. pylori and NSAID use should raise suspicion for other etiologies. Zollinger-Ellison syndrome (ZES), a condition caused by a gastrin-secreting tumor (gastrinoma), leads to profound gastric acid hypersecretion and refractory peptic ulcers. Therefore, measuring a fasting serum gastrin level is the most appropriate next step to screen for ZES.

• A) Refer for surgical resection of the ulcer: While surgery may ultimately be needed for a non-healing ulcer, it is crucial to first exclude underlying causes like ZES that would not be cured by local resection.
• C) Switch to a different proton pump inhibitor: While there is some variation in metabolism, it is unlikely that switching to another PPI would lead to healing of a truly refractory ulcer. Investigating the cause is more important.
• D) Add sucralfate and continue PPI therapy: Adding sucralfate is unlikely to be effective for an ulcer that has failed to heal with 12 weeks of maximal acid suppression. The focus should be on diagnosing the cause of the refractory nature of the ulcer.

This patient is presenting with acute upper gastrointestinal bleeding and signs of hemorrhagic shock (hypotension, tachycardia, pallor, diaphoresis). The immediate priority in managing any hemodynamically unstable patient is resuscitation. This involves securing the airway, breathing, and circulation (ABCs). In this case, establishing IV access and initiating aggressive fluid resuscitation with crystalloids (e.g., normal saline or lactated Ringer's solution) is the most critical first step to restore intravascular volume and improve tissue perfusion. Blood products should be administered if the patient does not respond to initial fluid resuscitation or has a very low hemoglobin.

• A) Administer intravenous octreotide: Octreotide is used specifically for suspected variceal bleeding. While this is a possibility, resuscitation takes precedence, and the etiology is not yet known.
• B) Perform urgent upper endoscopy: Endoscopy is crucial for diagnosis and treatment but should only be performed after the patient is hemodynamically stabilized through resuscitation.
• C) Administer intravenous pantoprazole: A PPI should be given, but it is not the most immediate life-saving intervention. Hemodynamic stabilization is the priority.